Subtype
Lung Neuroendocrine Neoplasm
CI-CAN-00001096Explore in graph →
Non-malignant399 active trials6 approved drugs6 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001096Explore in graph →
Clinical trials
1,149 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00927875 | A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 | 5 | Bristol-Myers SquibbINDUSTRY | 5 | Jun 3, 2013 | clinicaltrials |
| NCT01079481 | Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 1 | 21 | Samsung Medical CenterOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00697476 | Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC | terminated | Phase 1 / Phase 2 | 2 | Armando Santoro, MDOTHER | 1 | May 29, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00017251 | Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00065429 | Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 64 | ImmunoGen, Inc.INDUSTRY | 1 | Jul 18, 2012 | clinicaltrials |
| NCT00397293 | Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | Ascenta TherapeuticsINDUSTRY | 3 | Aug 24, 2010 | clinicaltrials |
| NCT00423254 | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. | completed | Phase 1 | 12 | Mannkind CorporationINDUSTRY | 1 | Aug 3, 2010 | clinicaltrials |
| NCT00447421 | A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy | terminated | Phase 1 / Phase 2 | 9 | Eli Lilly and CompanyINDUSTRY | 2 | Oct 28, 2009 | clinicaltrials |
| NCT00252889 | Doxil Topotecan Doublet Cancer Study | completed | Phase 1 | 20 | Christiana Care Health ServicesOTHER | 1 | Jan 27, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Jun 3, 2013source: clinicaltrials